Ceftiofur

DB11485ExperimentalVet approvedSmall molecule

Ceftiofur is a third generation cephalosporin antibiotic, first described in 1987, and now used in veterinary medicine. It is marketed by pharmaceutical company Zoetis as Excenel, and is the active... It is resistant to hydrolysis by beta-lactamase, and has activity against both Gram-positive and Gram-negative bacteria.

Mechanism: Pharmacologically active on Penicillin-binding protein
Curator reviewed
Formula / weight: C₁₉H₁₇N₅O₇S₃ · 523.55 g/mol (avg)
Also known as: Ceftiofur crystalline free acid

Resolves to

Compound

UNII83JL932I1CCAS80370-57-6ChEMBLCHEMBL222913KEGGD07657

Clinical / RWD

RxNorm1311521

Structure

InChIKeyZBHXIWJRIFEVQY-IHMPYVIRSA-NSMILES[H][C@]12SCC(CSC(=O)C3=CC=CO3)=C(N1C(=O)[C@H]2NC(=O)C(=N/OC)\C1=CSC(N)=N1)C(O)=O

What you can answer from here — as of September 13, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

56Drug interactionsStructured to mechanism, not free text

2+ReferencesStructured and connected to the statements they support

Which companies are running trials of Ceftiofur, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account